Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of relacorilant in endogenous Cushing syndrome
NL-OMON53993Phase 2Recruiting
- Sponsor
- Corcept Therapeutics
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of relacorilant in endogenous Cushing's syndrome, sponsored by Corcept Therapeutics. Started May 2022; status: recruiting.
02
Drugs
relacorilant
03
Conditions
endogenous Cushing's syndrome
Beyond the preview
Go deeper on NL-OMON53993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53993.